MENU
TRVI
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Trevi Therapeutics (TRVI) Ownership - Who owns Trevi Therapeutics?

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC... Show more

Profile

Industry
Pharmaceuticals Major
Address
195 Church Street
Phone
+1 203 304-2499
Employees
25
Web
https://www.trevitherapeutics.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
1.92B
P/E Ratio
N/A
Total Cash
171.78M
Projected Growth
N/A
Total Debt
682K
Revenue
N/A
Risk (Beta)
0.09
Dividend Yield
N/A
Total Cash/Share
1.21
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
View a ticker or compare two or three
TRVI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer and manufacturer of neurological products

Industry Biotechnology

Profile
Details
Industry
Pharmaceuticals Major
Address
195 Church Street
Phone
+1 203 304-2499
Employees
25
Web
https://www.trevitherapeutics.com